Multimodal drugs and their future for Alzheimer's and Parkinson's disease

Amenta, 2008, Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction, Curr. Med. Chem., 15, 488, 10.2174/092986708783503203 Bachurin, 2001, Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer, Ann. N. Y. Acad. Sci., 939, 425, 10.1111/j.1749-6632.2001.tb03654.x Barbiero, 2011, Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease, Behav. Brain Res, 216, 186, 10.1016/j.bbr.2010.07.033 Bezprozvanny, 2010, The rise and fall of Dimebon, Drug News Perspect., 23, 518, 10.1358/dnp.2010.23.8.1500435 Bordet, 2006, PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases, Biochem. Soc. Trans., 34, 1341, 10.1042/BST0341341 Breidert, 2002, Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease, J. Neurochem., 82, 615, 10.1046/j.1471-4159.2002.00990.x Butterfield, 2001, Brain oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins, Mech. Ageing Dev., 122, 945, 10.1016/S0047-6374(01)00249-4 Chen, 2001, Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease, J. Neurosci., 21, RC143, 10.1523/JNEUROSCI.21-10-j0001.2001 Chen, 2007, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease, Clin. Ther., 29, 1825, 10.1016/j.clinthera.2007.09.021 Chen, 2009, Cisd2 mediates mitochondrial integrity and life span in mammals, Autophagy, 5, 1043, 10.4161/auto.5.7.9351 Chimenti, 2006, Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors, Curr. Med. Chem., 13, 1411, 10.2174/092986706776872907 Choi, 2010, Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity, Proc. Natl. Acad. Sci. USA, 107, 21990, 10.1073/pnas.1006091107 Colca, 2004, Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe, Am. J. Physiol. Endocrinol. Metab., 286, E252, 10.1152/ajpendo.00424.2003 Collino, 2006, Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion, Eur. J. Pharmacol., 530, 70, 10.1016/j.ejphar.2005.11.049 Combs, 2000, Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists, J. Neurosci., 20, 558, 10.1523/JNEUROSCI.20-02-00558.2000 Culman, 2007, PPAR-gamma: therapeutic target for ischemic stroke, Trends Pharmacol. Sci., 28, 244, 10.1016/j.tips.2007.03.004 Dall'Igna, 2003, Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity, Br. J. Pharmacol., 138, 1207, 10.1038/sj.bjp.0705185 Dall'Igna, 2004, Caffeine as a neuroprotective adenosine receptor antagonist, Ann. Pharmacother., 38, 717, 10.1345/aph.1D307 Di Monte, 2003, The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?, Lancet Neurol., 2, 531, 10.1016/S1474-4422(03)00501-5 Fahn, 1992, The oxidant stress hypothesis in Parkinson's disease: evidence supporting it, Ann. Neurol., 32, 804, 10.1002/ana.410320616 Fernandez, 2009, Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial, Parkinsonism Relat. Disord, 16, 16, 10.1016/j.parkreldis.2009.06.008 Foley, 2008, The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats, Neuropharmacology, 54, 1166, 10.1016/j.neuropharm.2008.03.012 Fowler, 1980, The effect of age on the activity and molecular properties of human brain monoamine oxidase, J. Neural Transm., 49, 1, 10.1007/BF01249185 Fowler, 1997, Age-related increases in brain monoamine oxidase B in living healthy human subjects, Neurobiol. Aging, 18, 431, 10.1016/S0197-4580(97)00037-7 Gaeta, 2005, The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy, Br. J. Pharmacol., 146, 1041, 10.1038/sj.bjp.0706416 Gautier, 2003, Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function, Stroke, 34, 2975, 10.1161/01.STR.0000101914.62066.7B Geldenhuys, 2010, Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening, Bioorg. Med. Chem. Lett., 20, 5295, 10.1016/j.bmcl.2010.06.128 Geldenhuys, 2010, Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET, Bioorg. Med. Chem. Lett., 20, 819, 10.1016/j.bmcl.2009.12.088 Glennon, 2010, The medicinal chemistry of 5-HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs, Curr. Top. Med. Chem., 10, 579, 10.2174/156802610791111542 Hauptmann, 1996, The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA, Arch. Biochem. Biophys., 335, 295, 10.1006/abbi.1996.0510 Hauser, 2008, Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations, Mov. Disord., 23, 2177, 10.1002/mds.22095 Haycox, 2009, Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation, Drugs Aging, 26, 791, 10.2165/11316770-000000000-00000 Heneka, 2005, Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice, Brain, 128, 1442, 10.1093/brain/awh452 Herrine, 1999, Severe hepatotoxicity associated with troglitazone, Ann. Intern. Med., 130, 163, 10.7326/0003-4819-130-2-199901190-00021 Hindo, 2009, Small molecule modulators of copper-induced Abeta aggregation, J. Am. Chem. Soc., 131, 16663, 10.1021/ja907045h Honda, 2008, Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders, J. Mol. Cell. Cardiol., 44, 915, 10.1016/j.yjmcc.2008.03.004 Jacobson, 2006, Adenosine receptors as therapeutic targets, Nat. Rev. Drug Discov., 5, 247, 10.1038/nrd1983 Jenner, 2009, Adenosine, adenosine A 2A antagonists, and Parkinson's disease, Parkinsonism Relat. Disord., 15, 406, 10.1016/j.parkreldis.2008.12.006 Ji, 2009, Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome, Exp. Neurol., 216, 321, 10.1016/j.expneurol.2008.12.007 Joghataie, 2004, Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence, Parkinsonism Relat. Disord., 10, 465, 10.1016/j.parkreldis.2004.06.004 Kaundal, 2009, Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils, J. Pharmacol. Sci., 109, 361, 10.1254/jphs.08246FP Kohen, 1996, Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor, J. Neurochem., 66, 47, 10.1046/j.1471-4159.1996.66010047.x Kummer, 2008, PPARs in Alzheimer's disease, PPAR Res., 2008, 403896, 10.1155/2008/403896 Langston, 1983, Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, N. Engl. J. Med., 309, 310, 10.1056/NEJM198308043090511 Lee, 2009, PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia, Biochem. Biophys. Res. Commun., 380, 17, 10.1016/j.bbrc.2008.12.181 Lermontova, 2000, Dimebon improves learning in animals with experimental Alzheimer's disease, Bull. Exp. Biol. Med., 129, 544, 10.1007/BF02434871 LeWitt, 2008, Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005), Ann. Neurol., 63, 295, 10.1002/ana.21315 Li, 2008, Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat, Cardiovasc. Drugs Ther., 22, 283, 10.1007/s10557-008-6115-x Lin, 2007, Crystal structure of human mitoNEET reveals distinct groups of iron sulfur proteins, Proc. Natl. Acad. Sci. USA, 104, 14640, 10.1073/pnas.0702426104 Luna-Medina, 2005, Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation, J. Biol. Chem., 280, 21453, 10.1074/jbc.M414390200 Maia, 2002, Does caffeine intake protect from Alzheimer's disease?, Eur. J. Neurol., 9, 377, 10.1046/j.1468-1331.2002.00421.x Mancino, 2009, Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited, Inorg. Chem., 48, 9596, 10.1021/ic9014256 Morelli, 2009, Adenosine A2A receptors and Parkinson's disease, Handb. Exp. Pharmacol., 193, 589, 10.1007/978-3-540-89615-9_18 Morphy, 2005, Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem., 48, 6523, 10.1021/jm058225d Morphy, 2004, From magic bullets to designed multiple ligands, Drug Discov. Today, 9, 641, 10.1016/S1359-6446(04)03163-0 Navarro, 2009, Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease, J. Bioenerg. Biomembr., 41, 517, 10.1007/s10863-009-9250-6 Nowakowska, 2001, Investigating potential anxiolytic, antidepressant and memory enhancing activity of deprenyl, J. Physiol. Pharmacol., 52, 863 Nunomura, 2001, Oxidative damage is the earliest event in Alzheimer disease, J. Neuropathol. Exp. Neurol., 60, 759, 10.1093/jnen/60.8.759 Olanow, 2009, A double-blind, delayed-start trial of rasagiline in Parkinson's disease, N. Engl. J. Med., 361, 1268, 10.1056/NEJMoa0809335 Paddock, 2007, MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone, Proc. Natl. Acad. Sci. USA, 104, 14342, 10.1073/pnas.0707189104 Patzer, 2008, Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia, Eur. J. Neurosci., 28, 1786, 10.1111/j.1460-9568.2008.06478.x Pieper, 2010, Discovery of a proneurogenic, neuroprotective chemical, Cell, 142, 39, 10.1016/j.cell.2010.06.018 Prediger, 2005, Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors, Neurobiol. Aging, 26, 957, 10.1016/j.neurobiolaging.2004.08.012 Prediger, 2005, Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD)—the spontaneously hypertensive rat (SHR), Int. J. Neuropsychopharmacol., 8, 583, 10.1017/S1461145705005341 Quinn, 2008, The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B, Br. J. Pharmacol., 154, 226, 10.1038/bjp.2008.78 Reinikainen, 1990, Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy, J. Neurosci. Res., 27, 576, 10.1002/jnr.490270419 Rennings, 2010, Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome, Eur. Heart J., 31, 983, 10.1093/eurheartj/ehp562 Sagi, 2003, Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor, J. Neurochem., 86, 290, 10.1046/j.1471-4159.2003.01801.x Sano, 1997, A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study, N. Engl. J. Med., 336, 1216, 10.1056/NEJM199704243361704 Saura, 1994, Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography, Neuroscience, 62, 15, 10.1016/0306-4522(94)90311-5 Sayre, 2008, Oxidative stress and neurotoxicity, Chem. Res. Toxicol., 21, 172, 10.1021/tx700210j Schapira, 2008, Drug selection and timing of initiation of treatment in early Parkinson's disease, Ann. Neurol., 64, S47 Shadrina, 2010, Molecular mechanisms of pathogenesis of Parkinson's disease, Int. Rev. Cell Mol. Biol., 281, 229, 10.1016/S1937-6448(10)81006-8 Shastry, 2003, Neurodegenerative disorders of protein aggregation, Neurochem. Int., 43, 1, 10.1016/S0197-0186(02)00196-1 Shimazu, 2005, A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia, Stroke, 36, 353, 10.1161/01.STR.0000152271.21943.a2 Soong, 1992, Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain, Nat. Genet., 2, 318, 10.1038/ng1292-318 Strolin Benedetti, 1989, Monoamine oxidase, brain ageing and degenerative diseases, Biochem. Pharmacol., 38, 555, 10.1016/0006-2952(89)90198-6 Terry, 1987, Neocortical cell counts in normal human adult aging, Ann. Neurol., 21, 530, 10.1002/ana.410210603 Tsunekawa, 2008, Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25–35), Behav. Brain Res., 190, 224, 10.1016/j.bbr.2008.03.002 Van der Schyf, 2007, Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties, Curr. Alzheimer Res., 4, 522, 10.2174/156720507783018226 Weinreb, 2008, The neuroprotective mechanism of action of the multimodal drug ladostigil, Front. Biosci., 13, 5131, 10.2741/3069 Weinreb, 2008, The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity, Chem. Biol. Interact., 175, 318, 10.1016/j.cbi.2008.05.038 Weinreb, 2009, Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs, Neurotherapeutics, 6, 163, 10.1016/j.nurt.2008.10.030 Weinstock, 2011, Ladostigil prevents age-related glial activation and spatial memory deficits in rats, Neurobiol. Aging, 32, 1069, 10.1016/j.neurobiolaging.2009.06.004 Wiley, 2007, MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity, Proc. Natl. Acad. Sci. USA, 104, 5318, 10.1073/pnas.0701078104 Wiley, 2007, The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster, J. Biol. Chem., 282, 23745, 10.1074/jbc.C700107200 Wu, 2009, Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation, Circulation, 119, 1124, 10.1161/CIRCULATIONAHA.108.812537 Yan, 2003, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, J. Neurosci., 23, 7504, 10.1523/JNEUROSCI.23-20-07504.2003 Yi, 2008, PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms, Brain Res., 1244, 164, 10.1016/j.brainres.2008.09.074 Yogev-Falach, 2002, Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline, FASEB J., 16, 1674, 10.1096/fj.02-0198fje Youdim, 2005, CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases, J. Neural Transm., 112, 519, 10.1007/s00702-004-0214-z Youdim, 2005, Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders, Trends Pharmacol. Sci., 26, 27, 10.1016/j.tips.2004.11.007 Youdim, 2007, Magic bullets or novel multimodal drugs with various targets for Parkinson's Disease?, Nat. Rev. Drug Discov., 6, iii, 10.1038/nrd2330 Youdim, 2006, The therapeutic potential of monoamine oxidase inhibitors, Nat. Rev. Neurosci., 7, 295, 10.1038/nrn1883 Yu, 2010, Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system, Neuropathol. Appl. Neurobiol., 36, 612, 10.1111/j.1365-2990.2010.01107.x Zheng, 2009, Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective-Neurorestorative Moieties for Alzheimer's Therapy, J. Med. Chem, 52, 4095, 10.1021/jm900504c Zheng, 2010, New selective acetylcholinesterase inhibitor with site-activated chelating, neurorescuing and anti-amyloid activities for Alzheimer's therapy, ACS Chem. Neurosci, 1, 737, 10.1021/cn100069c Zheng, 2010, Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy, ACS Chem. Biol., 5, 603, 10.1021/cb900264w Zimmermann, 2007, Multi-target therapeutics: when the whole is greater than the sum of the parts, Drug Discov. Today, 12, 34, 10.1016/j.drudis.2006.11.008